Form 4: Coherus Oncology CEO's Tax-Related Stock Withholding

Coherus Oncology's President & CEO, Dennis M. Lanfear, reported the withholding of 11,839 common shares by the issuer for tax liabilities related to restricted stock unit vesting.

Summary

• Dennis M. Lanfear, President & CEO and Director of Coherus Oncology, Inc. (CHRS), reported a transaction on January 20, 2026.
• The transaction involved the disposition of 11,839 shares of Common Stock at a price of $1.55 per share.
• These shares were automatically withheld by Coherus Oncology to cover tax liabilities associated with the vesting of restricted stock units, as per Rule 16b-3.
• No shares were sold by Mr. Lanfear in connection with this transaction.
• Following the transaction, Mr. Lanfear directly beneficially owns 673,235 shares of Common Stock.
• Additionally, 432,684 shares are indirectly held by the Lanfear Revocable Trust, and 86,965 shares are indirectly held by Lanfear Capital Advisors, LLC.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary insider transaction (shares withheld for tax liability) which is neutral in sentiment. It does not indicate any positive or negative operational or financial developments for the company.

Positives

• The transaction was not a discretionary sale by the CEO, but rather a routine withholding for tax obligations related to vested restricted stock units.
• The CEO continues to hold a significant number of shares, both directly and indirectly through trusts and LLCs, indicating continued alignment with shareholder interests.

Negatives

• A reduction in direct beneficial ownership of 11,839 shares, although for a non-discretionary tax purpose.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: Minimal impact as the transaction is a routine tax withholding and not a discretionary sale, indicating continued insider ownership.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction where shares were withheld for tax purposes related to restricted stock unit vesting. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The CEO continues to hold a substantial number of shares, maintaining alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Coherus Oncology, CHRS, Dennis M. Lanfear, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Tax Liability, Beneficial Ownership